datopotamab deruxtecan + ramucirumab

Datopotamab deruxtecan + ramucirumab is an investigational combination therapy for cancer, currently studied primarily in advanced solid tumors such as non-small cell lung cancer (NSCLC). Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate (ADC) that consists of a humanized anti-TROP2 antibody linked via a cleavable tetrapeptide linker to deruxtecan (DXd), a topoisomerase I inhibitor cytotoxic payload. Upon binding TROP2 on tumor cells, the drug is internalized, followed by release of DXd in the cell, resulting in DNA damage and cell death, with a bystander effect aiding destruction of neighboring tumor cells[1][2][6][8]. Ramucirumab is a monoclonal antibody directed against vascular endothelial growth factor receptor 2 (VEGFR2), acting as an angiogenesis inhibitor by blocking VEGF-mediated signaling. The combination is under evaluation for synergistic antitumor effects, thought to include enhanced tumor cell killing and disruption of tumor angiogenesis. This drug combination is jointly developed by Daiichi Sankyo and AstraZeneca (for datopotamab deruxtecan), and Eli Lilly (for ramucirumab).

Brand names

Datroway + ramucirumab

Other names

Dato-DXd + ramucirumab